je.st
news
Tag: grass
Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet)
2014-02-03 14:30:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. GRASTEK (Timothy Grass Pollen Allergen Extract) Remains Under FDA Review in the United States WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the regulatory approval and launch of GRASTEK (Timothy grass pollen allergen extract) sublingual tablets in Canada. This represents the first approval of GRASTEK for Merck. The product is currently marketed by ALK-Abello in Europe as GRAZAX. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: approval
canadian
grass
extract
Scotts to test genetically modified grass in residential lawns
2014-02-01 14:57:25| Chemicals - Topix.net
Until now, genetically modified plants have mainly been grown in large agricultural fields away from urban areas.
Tags: test
modified
residential
grass
Damaged power lines spark grass fire
2014-01-27 00:10:41| Energy - Topix.net
Damaged power lines sparked a grass fire in midtown this week. Public Service Company of OKlahoma crews told FOX23 News that strong winds knocked the power lines out of place near 15th and Harvard.
Merck Statement on FDA Advisory Committee for GRASTEK (Timothy Grass Pollen Allergen Extract), Mercks Investigational Sublingual Allergy Immunotherapy Tablet
2013-12-13 01:17:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued the following statement after the conclusion of the Allergenic Products Advisory Committee of the U.S. Food and Drug Administration (FDA) meeting to discuss GRASTEK (Timothy grass pollen allergen extract). Language: English Contact: MerckMedia:Pamela Eisele, 908-423-5042orRobert Consalvo, 908-423-6595orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: statement
committee
advisory
grass
Mercks Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study
2013-11-09 18:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Data to be Presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced data for its investigational Timothy grass sublingual allergy immunotherapy tablet (MK-7243) from a study involving 1,501 North American adult and pediatric patients. Language: English Contact: For MerckMedia:Pam Eisele, 908-423-5042orRobert Consalvo, 908-423-6595orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: study
iii
children
reduced
Sites : [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] next »